<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511446</url>
  </required_header>
  <id_info>
    <org_study_id>AIO STO-0601</org_study_id>
    <nct_id>NCT00511446</nct_id>
  </id_info>
  <brief_title>Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer</brief_title>
  <official_title>Phase II Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination regimens of 3 active drugs have shown promising activity in treatment of
      metastatic gastric cancer. Docetaxel combined with cisplatin and 5-fluorouracil (FU) yielded
      superior overall survival and response rates when compared to standard cisplatin and 5-FU.
      However, a toxicity profile showed the need for development of less toxic modifications. In a
      prior phase I trial, the maximum tolerated dose was defined. In this phase II trial, a first
      evaluation of activity will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety/toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of resections with curative intent</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel, oxaliplatin, capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, oxaliplatin, capecitabine</intervention_name>
    <description>Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>xeloda</other_name>
    <other_name>taxotere</other_name>
    <other_name>eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histologically proven irresectable, metastatic or recurrent adenocarcinoma of the
             stomach or the gastroesophageal junction, i.e., Tx-4 M1 or T4 M0

          -  Irresectable (as judged by an experienced surgeon):

               1. T4 infiltrating of several organs

               2. T4 infiltrating one organ, but irresectable

               3. T4 infiltrating one organ, respectable, but inoperable patient

          -  The nodal status is neglected

          -  Measurable disease according to RECIST

          -  ECOG Performance Status ≤ 2

          -  Male or female patients aged ≥ 18 years

          -  Life expectancy ≥ 3 months

          -  Adequate bone marrow, hepatic and renal function:

               1. Haemoglobin &gt; 9.0 g/dL (transfusions allowed to achieve or maintain levels)

               2. Absolute neutrophil count &gt; 1.5 x 10^9/L

               3. Platelet count &gt; 100 x 10^9/L

               4. ALAT, ASAT &lt; 3.5 x ULN

               5. Alkaline phosphatase &lt; 6 x ULN

               6. Total bilirubin &lt; 1.0 x ULN

               7. Creatinine clearance &gt; 50 mL/min (calculated according to Cockroft and Gault)

          -  Prior surgery must be more than 28 days ago

          -  Positive nodes as diagnosed on endorectal ultrasound and/or MRI (tumour is staged by
             preferably a high resolution MRI; if MRI is not available, locoregional staging must
             be performed by computed tomography plus endorectal ultrasound)

          -  Tumor staging must be done within 28 days from the start of the treatment

          -  Negative pregnancy test in women with childbearing of potential (within 7 days prior
             to the start of the chemotherapy)

               -  Postmenopausal women must have been amenorrheic for at least 12 months to be
                  considered of non-childbearing potential

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy or radiotherapy (a neoadjuvant or adjuvant chemotherapy
             must be completed and without progression for at least 6 months)

          -  Previous (within the last 5 years) or concurrent malignancies, with the exception of
             adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin

          -  Peripheral neuropathy ≥ grade 2 (according to NCI CTCAE v 3.0)

          -  Patient must not have been treated with any investigational drug, agent nor procedure,
             (i.e., did not participate in another trial within 30 days) before entry in this trial

          -  Known allergy or any other adverse reaction to any of the study drugs or to any
             related compound

          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or
             chemically related analogues, such as brivudine

          -  Clinically significant concomitant diseases, such as:

               1. Active infection necessitating systemic antibiotics

               2. Interstitial lung diseases

               3. Chronic diarrhea, inflammatory bowel disease

               4. Neurological or psychiatric disease, dementia, epilepsy or untreated brain
                  metastases

          -  Cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease
             and cardiac arrhythmia not well controlled with medication) or myocardial infarction
             or resuscitation within the last 6 months

          -  Pregnant or lactating women are excluded

          -  Presence of adequate contraception in fertile patients (methods of adequate
             contraception are: intra-uterine device, hormonal contraception, vasectomy, tubal
             ligation or abstinence)

          -  Alcohol or drug abuse

          -  Ability to swallow tablets

          -  Psychological, familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Joachim Schmoll, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martin-Luther-University Halle-Wittenberg, Medical Faculty</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite - Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik - Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Osthessen</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-University Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum St. Georg</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSP Lörrach-Rheinfelden</name>
      <address>
        <city>Lörrach</city>
        <zip>79539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>Arbeitsgemeinschaft Internistische Onkologie</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Hans-Joachim Schmoll, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Stomach neoplasms</keyword>
  <keyword>docetaxel</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

